ES2793942T3 - Vacunas líquidas estables contra virus porcino - Google Patents

Vacunas líquidas estables contra virus porcino Download PDF

Info

Publication number
ES2793942T3
ES2793942T3 ES15704809T ES15704809T ES2793942T3 ES 2793942 T3 ES2793942 T3 ES 2793942T3 ES 15704809 T ES15704809 T ES 15704809T ES 15704809 T ES15704809 T ES 15704809T ES 2793942 T3 ES2793942 T3 ES 2793942T3
Authority
ES
Spain
Prior art keywords
stable liquid
vaccine
virus
live attenuated
liquid vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15704809T
Other languages
English (en)
Spanish (es)
Inventor
Kevin O'connell
Zhisong Qiao
Brad Eddy
Erin Strait
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Application granted granted Critical
Publication of ES2793942T3 publication Critical patent/ES2793942T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A61K39/225—Porcine transmissible gastroenteritis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ES15704809T 2014-02-19 2015-02-18 Vacunas líquidas estables contra virus porcino Active ES2793942T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461941720P 2014-02-19 2014-02-19
PCT/EP2015/053364 WO2015124594A1 (en) 2014-02-19 2015-02-18 Swine virus vaccines that are liquid stable

Publications (1)

Publication Number Publication Date
ES2793942T3 true ES2793942T3 (es) 2020-11-17

Family

ID=52473920

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15704809T Active ES2793942T3 (es) 2014-02-19 2015-02-18 Vacunas líquidas estables contra virus porcino

Country Status (9)

Country Link
US (1) US9855336B2 (enExample)
EP (1) EP3107572B1 (enExample)
JP (1) JP6596008B2 (enExample)
CN (1) CN106061503B (enExample)
BR (1) BR112016018871B1 (enExample)
ES (1) ES2793942T3 (enExample)
RU (1) RU2695523C2 (enExample)
TW (1) TWI670085B (enExample)
WO (1) WO2015124594A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) * 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
WO2017162720A1 (en) * 2016-03-23 2017-09-28 Intervet International B.V. A vaccine for intradermal application against pcv2 and prrs virus infection
JP2019509302A (ja) 2016-03-23 2019-04-04 インターベット インターナショナル ベー． フェー． アルブミンを含むｐｃｖ２及びｐｒｒｓウイルス感染症に対する混合ワクチン
CN107686833B (zh) * 2016-04-18 2021-02-19 华南农业大学 一种猪细小病毒毒株及其应用
EP3548077A1 (en) * 2016-11-29 2019-10-09 Intervet International B.V. Swine vaccine
NL2018155B1 (en) * 2017-01-11 2018-07-25 Intervet Int Bv Oral vaccine against ruminant respiratory disease
JP7162072B2 (ja) 2018-03-26 2022-10-27 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド 免疫原性組成物を製造する方法
CN109316603A (zh) * 2018-10-31 2019-02-12 南京大爻网络科技有限公司 一种猪支原体肺炎活疫苗耐热冷冻保护剂、制备方法及应用
CN113646047B (zh) * 2019-02-15 2025-07-08 印度血清研究所私人有限公司 减毒活流感疫苗组合物和用于制备其的方法
EP4013436A1 (en) * 2019-08-14 2022-06-22 Leukocare Ag Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CA3185751A1 (en) * 2020-07-24 2022-01-27 Edgar DIAZ Combination porcine vaccine
CN113559256B (zh) * 2021-08-09 2024-03-29 广州科力生物科技有限公司 一种诺卡氏菌免疫增强剂及其在制备猪用疫苗中的应用
CN118215488A (zh) * 2021-10-20 2024-06-18 舒万诺知识产权公司 含有磷酸盐和精氨酸的组合物以及此类组合物用于毒力抑制的递送
CN114891121B (zh) * 2022-05-11 2024-01-19 天康制药股份有限公司 一种抗pedv和prv的二联病毒样颗粒疫苗及其制备方法
CN114931648B (zh) * 2022-06-15 2024-02-27 金宇保灵生物药品有限公司 一种猪流行性腹泻和猪传染性胃肠炎二联活疫苗耐热保护剂及其制备方法和应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155589A (en) 1958-04-14 1964-11-03 Upjohn Co Parenteral extravascular injectable vaccines for simultaneous immunization of canidae against rabies, canine distemper, and infectious canine hepatitis
US3526696A (en) 1968-02-14 1970-09-01 Lilly Co Eli Shipping fever vaccine
GB1575155A (en) 1978-04-11 1980-09-17 Merck & Co Inc Vaccine stabilizer
PT71926B (en) * 1979-10-29 1982-03-31 Merck & Co Inc Process for preparing a liquid vaccine comprising a stabilizer
US4337242A (en) 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
JPS589688A (ja) 1981-07-06 1983-01-20 Toyobo Co Ltd 安定な酵素組成物
JPS6153227A (ja) 1984-08-23 1986-03-17 Biseibutsu Kagaku Kenkyusho:Kk 日本脳炎・豚パルボウイルス感染症混合生ワクチン
US4867975A (en) 1988-01-27 1989-09-19 University Of Delaware Live attenuated temperature-sensitive avian infectious bronchitis virus vaccines and preparation and use thereof
AU2088992A (en) 1992-05-05 1993-11-11 Research Foundation For Microbial Diseases Of Osaka University, The Stabilized live vaccine
US5443959A (en) 1992-09-09 1995-08-22 Tokuyama Corporation Method of assaying fibrinogen, dry reagent therefor, and process for the preparation thereof
EP0650734B1 (en) 1993-10-28 1999-03-10 Division Of Microbiology, Kyoto Biken Laboratories, Inc. Pentavalent live viral vaccine
FR2719479B1 (fr) 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US5565318A (en) 1994-09-02 1996-10-15 Pharmacia Biotech, Inc. Room temperature stable reagent semi-spheres
US5593824A (en) 1994-09-02 1997-01-14 Pharmacia Biotech, Inc. Biological reagent spheres
FR2742756B1 (fr) 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US5932223A (en) 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
NZ514103A (en) 1997-09-25 2001-09-28 Biotechnology Res & Dev LktA deletion mutant of P. haemolytica
CN1053590C (zh) 1998-10-19 2000-06-21 卫生部长春生物制品研究所 冻干甲型肝炎减毒活疫苗及其保护剂
JP5490972B2 (ja) 2000-08-04 2014-05-14 中外製薬株式会社 タンパク質注射製剤
EP2591771A1 (en) 2002-04-11 2013-05-15 MedImmune, LLC Preservation of bioactive materials by freeze dried foam
RS20050177A (sr) 2002-08-26 2007-06-04 Pfizer Products Inc., Vakcina za infekcije respiratornog i reproduktivnog sistema kod stoke
US6931888B2 (en) 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
CN101804202B (zh) * 2003-02-25 2014-06-18 米迪缪尼有限公司 制备流感疫苗组合物的方法
US7351416B2 (en) 2003-07-02 2008-04-01 The United States Of America As Represented By The Department Of Agriculture Vaccines comprising acapsular P. multocida hyaE deletion mutants
US20070148765A1 (en) 2003-11-19 2007-06-28 Evans Robert K Preservative-containing virus formulations
MX2007005379A (es) * 2004-11-05 2007-07-04 Wellstat Biologics Corp Formulaciones de virus envueltos estables y filtrables.
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US20070259348A1 (en) 2005-05-03 2007-11-08 Handylab, Inc. Lyophilized pellets
RS51996B (sr) 2005-09-16 2012-04-30 Merial Ltd. Stabilizatori za vakcine osušene zamrzavanjem
KR101357685B1 (ko) * 2005-11-21 2014-02-06 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 재조합 바이러스용 안정화 제형
WO2007064191A1 (en) 2005-12-02 2007-06-07 Stichting Katholieke Universiteit Method for obtaining hollow particles
CA2932997C (en) 2006-01-24 2019-07-30 Nexbio, Inc. Technology for preparation of macromolecular microspheres
ES2365832T3 (es) 2007-03-05 2011-10-11 Cadila Healthcare Limited Composiciones que comprenden conjugados de peg-interferón alfa y rafinosa como crioprotector.
MY180465A (en) 2007-04-06 2020-11-30 Takeda Vaccines Inc Methods and compositions for live attenuated viruses
JP5307801B2 (ja) 2007-05-18 2013-10-02 メディミューン・エルエルシー 凍結乾燥フォームによる生物活性材料の防腐
AU2008266120B2 (en) 2007-06-14 2013-06-20 The Board Of Regents For Oklahoma State University Vaccines containing canine parvovirus genetic variants
TWI436789B (zh) 2008-01-21 2014-05-11 Intervet Int Bv 含有藥學化合物的顆粒之冷凍乾燥方法及含有此顆粒的藥學包
CA2716399C (en) 2008-03-05 2020-07-21 Pierre Chouvenc Process for stabilizing an adjuvant containing vaccine composition
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
US7998488B2 (en) 2008-11-14 2011-08-16 Baxter International Inc. Vaccine formulations and uses thereof
CA2742817A1 (en) 2008-11-20 2010-05-27 Biogen Idec Ma Inc. Arginine inactivation of viruses
US8647637B2 (en) 2009-01-30 2014-02-11 The Board Of Regents For Oklahoma State University Immunogenic compositions, vaccines and diagnostics based on canine distemper viruses circulating in north american dogs
TWI471127B (zh) 2009-04-29 2015-02-01 Intervet Int Bv 供人類使用之口服崩解錠劑的製備方法、所製得之口服崩解錠劑、以及含有該口服崩解錠劑的包裝物
TWI468157B (zh) 2009-04-29 2015-01-11 Intervet Int Bv 形成錠劑的方法，進行該方法的系統及包含該錠劑的包裝物
US8557253B2 (en) 2009-10-07 2013-10-15 Sanofi Pasteur Sa Stabilizing excipient for inactivated whole virus vaccine
US8357401B2 (en) 2009-12-11 2013-01-22 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
CN103370078B (zh) * 2011-02-17 2016-08-10 贝林格尔.英格海姆维特梅迪卡有限公司 新的欧洲型猪生殖与呼吸综合征病毒株
US20140017318A1 (en) 2012-07-10 2014-01-16 Kevin O'Connell Method to produce a medicinal product comprising a biologically active protein and the resulting product
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) * 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗

Also Published As

Publication number Publication date
EP3107572A1 (en) 2016-12-28
RU2016137121A (ru) 2018-03-26
EP3107572B1 (en) 2020-04-22
US9855336B2 (en) 2018-01-02
RU2016137121A3 (enExample) 2018-10-03
RU2695523C2 (ru) 2019-07-23
JP2017506643A (ja) 2017-03-09
BR112016018871B1 (pt) 2024-02-27
TW201613556A (en) 2016-04-16
TWI670085B (zh) 2019-09-01
JP6596008B2 (ja) 2019-10-23
CN106061503A (zh) 2016-10-26
WO2015124594A1 (en) 2015-08-27
CN106061503B (zh) 2020-06-16
BR112016018871A2 (enExample) 2017-08-15
US20170014513A1 (en) 2017-01-19

Similar Documents

Publication Publication Date Title
ES2793942T3 (es) Vacunas líquidas estables contra virus porcino
US9603924B2 (en) Bovine virus vaccines that are liquid stable
CN105992593B (zh) 液体稳定的家禽病毒疫苗
EP2887957B1 (en) Liquid stable virus vaccines
US9393298B2 (en) Liquid stable bovine virus vaccines
ES2749197T5 (es) Formulaciones secas de vacunas que son estables a la temperatura ambiente
RU2836910C9 (ru) Жидкие стабильные вакцины, содержащие вирус крупного рогатого скота
RU2836910C2 (ru) Жидкие стабильные вакцины, содержащие вирус крупного рогатого скота
NZ711697B2 (en) Liquid stable bovine virus vaccines
BR112016018750B1 (pt) Vacina líquida estável, uso de um vírus da bronquite infecciosa (ibv) vivo atenuado e método para fabricar uma vacina líquida estável contra o ibv